[1] |
Gru AA, Plaza JA, Sanches JA, et al. An update on Epstein⁃Barr virus⁃and human T⁃lymphotropic virus type⁃1⁃induced cutaneous manifestations. CME PartⅡ[J]. J Am Acad Dermatol, 2023,88(5):983⁃998. doi: 10.1016/j.jaad.2022.07.063.
|
[2] |
Campo E, Jaffe ES, Cook JR, et al. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee[J]. Blood, 2022,140(11):1229⁃1253. doi: 10.1182/blood.2022015851.
|
[3] |
Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms[J]. Leukemia, 2022,36(7):1720⁃1748. doi: 10.1038/s41375⁃022⁃01620⁃2.
|
[4] |
Okuno Y, Murata T, Sato Y, et al. Defective Epstein⁃Barr virus in chronic active infection and haematological malignancy[J]. Nat Microbiol, 2019,4(3):404⁃413. doi: 10.1038/s41564⁃018⁃0334⁃0.
|
[5] |
Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J]. Blood, 2016,127(20):2375⁃2390. doi: 10.1182/blood⁃2016⁃01⁃643569.
|
[6] |
Ohashi A, Uemura Y, Yoshimori M, et al. The plasma level of interleukin⁃1β can be a biomarker of angiopathy in systemic chronic active Epstein⁃Barr virus infection[J]. Front Microbiol, 2022,13:874998. doi: 10.3389/fmicb.2022.874998.
|
[7] |
中华医学会儿科学分会感染学组, 全国儿童EB病毒感染协作组. 儿童EB病毒感染相关疾病的诊断和治疗原则专家共识[J]. 中华儿科杂志, 2021,59(11):905⁃911. doi: 10.3760/cma.j.cn112140⁃20210618⁃00513.
|
[8] |
Shafiee A, Shamsi S, Kohandel Gargari O, et al. EBV associated T⁃ and NK⁃cell lymphoproliferative diseases: a comprehensive overview of clinical manifestations and novel therapeutic insights[J]. Rev Med Virol, 2022,32(4):e2328. doi: 10.1002/rmv.2328.
|
[9] |
Turnbull N, Hawkins D, Atkins M, et al. Persistent erythema multiforme associated with Epstein⁃Barr virus infection[J]. Clin Exp Dermatol, 2014,39(2):154⁃157. doi: 10.1111/ced.12243.
|
[10] |
Cohen JI, Manoli I, Dowdell K, et al. Hydroa vacciniforme⁃like lymphoproliferative disorder: an EBV disease with a low risk of systemic illness in whites[J]. Blood, 2019,133(26):2753⁃2764. doi: 10.1182/blood.2018893750.
|
[11] |
张燕林, 谢建兰, 郑媛媛, 等. EB病毒阳性T/NK细胞淋巴组织增殖性疾病156例临床病理学特征[J]. 中华病理学杂志, 2018,47(6):407⁃411. doi: 10.3760/cma.j.issn.0529⁃5807.2018. 06.004.
|
[12] |
Gotoh K, Ito Y, Shibata⁃Watanabe Y, et al. Clinical and virological characteristics of 15 patients with chronic active Epstein⁃Barr virus infection treated with hematopoietic stem cell transplantation[J]. Clin Infect Dis, 2008,46(10):1525⁃1534. doi: 10.1086/587671.
|
[13] |
Kawa K, Sawada A, Sato M, et al. Excellent outcome of allogeneic hematopoietic SCT with reduced⁃intensity conditioning for the treatment of chronic active EBV infection[J]. Bone Marrow Transplant, 2011,46(1):77⁃83. doi: 10.1038/bmt.2010. 122.
|
[14] |
Sawada A, Inoue M, Kawa K. How we treat chronic active Epstein⁃Barr virus infection[J]. Int J Hematol, 2017,105(4):406⁃418. doi: 10.1007/s12185⁃017⁃2192⁃6.
|